Michael G Oefelein

Michael is the Chief Medical Officer at LIPAC Oncology and TesoRx Pharma. Michael is a board certified physician and a Fellow of the American College of Surgeons with more than 15 years of experience in the pharmaceutical and medical device industries with a focus on dermatology, urology, oncology, ophthalmology and plastic and bariatric surgery.

Prior to joining TesoRx Pharma in 2014, Michael held leadership positions at Allergan and Digirad where he brought multiple drugs and devices from the laboratory to market including genitourinary oncology drugs Degarelix, Zometa and Apaziquone; non-oncology drugs Levaquin, Botox, Noctiva/Serenity-120; and devices Seriscaffold, breast implants, HA-fillers and surgical navigation systems. As a key opinion leader Michael has authored almost 100 peer reviewed publications, delivered scientific presentations at a variety of venues, led advisory boards, and designed and executed clinical trials for purposes ranging from registration trials to safety and pharmacoeconomic research. Michael holds multiple patents for his inventions.

Michael started his career in academia as an assistant professor of Urology and Oncology at the Ireland Cancer Center-Case Western Reserve University. Michael earned his undergraduate degree from the University of Rochester and went on to earn his medical degree from Case Western Reserve University and his post-graduate degree in Surgery and Urology from Northwestern University. In addition to maintaining a private practice, Michael is an active member of numerous medical societies including the Society of Urological Oncology; Society of Urodynamics, Female Pelvic Medicine, & Urogenital Reconstruction; American Urological Association; and the American College of Surgeons and Laparoscopic Surgeons.